XML 20 R46.htm IDEA: XBRL DOCUMENT v2.4.1.9
Debt - Additional Information (Detail) (Loan and Security Agreement, USD $)
In Millions, unless otherwise specified
0 Months Ended 3 Months Ended
Jun. 30, 2014
Tranche
Mar. 31, 2015
Jun. 30, 2014
Line of Credit Facility [Line Items]      
Maximum borrowing limit $ 30.0us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity   $ 30.0us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
Term of agreement 5 years    
Number of loan tranches 3cers_NumberOfEqualTranches    
Interest rate, description   Term Loan A bears an interest rate of 6.95%. Term Loan B and Term Loan C will bear an interest rate calculated at the greater of 6.95% or 6.72% plus the three month U.S. LIBOR rate in effect three business days prior to the applicable Term Loan funding date.  
Maturity period   Jun. 01, 2019  
Principal and interest payments 42 months    
Final payment term percent 7.00%cers_LineOfCreditFacilityFinalPaymentPercentageOfPrincipalDrawnAtMaturity    
Terms of required periodic payments of interest and principal   The Company is required to make interest only payments through December 2015 followed by forty-two months of equal principal and interest payments thereafter; however, if the Revenue Event is achieved no later than November 30, 2015, then the interest-only period may be extended through December 31, 2016, and the amortization period will be reduced to thirty months. The Company is also required to make a final payment equal to 7% of the principal amounts of the Term Loans drawn payable on the earlier to occur of maturity or prepayment.  
Securities Pledged as Collateral
     
Line of Credit Facility [Line Items]      
Percentage of investments made in subsidiary 35.00%cers_PercentageOfInvestmentsMadeInSubsidiary
/ us-gaap_FinancialInstrumentAxis
= us-gaap_SecuritiesPledgedAsCollateralMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
  35.00%cers_PercentageOfInvestmentsMadeInSubsidiary
/ us-gaap_FinancialInstrumentAxis
= us-gaap_SecuritiesPledgedAsCollateralMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
First Tranche (Term Loan A)      
Line of Credit Facility [Line Items]      
Loan and security agreement 10.0us-gaap_LineOfCredit
/ us-gaap_DebtInstrumentAxis
= cers_FirstTrancheMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
  10.0us-gaap_LineOfCredit
/ us-gaap_DebtInstrumentAxis
= cers_FirstTrancheMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
Interest rate 6.95%us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd
/ us-gaap_DebtInstrumentAxis
= cers_FirstTrancheMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
  6.95%us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd
/ us-gaap_DebtInstrumentAxis
= cers_FirstTrancheMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
Second Tranche (Term Loan B)      
Line of Credit Facility [Line Items]      
Loan and security agreement 10.0us-gaap_LineOfCredit
/ us-gaap_DebtInstrumentAxis
= cers_SecondTrancheMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
  10.0us-gaap_LineOfCredit
/ us-gaap_DebtInstrumentAxis
= cers_SecondTrancheMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
Borrowing conditions   The second tranche of $10.0 million ("Term Loan B") was contingent upon the approval, by the U.S. Food and Drug Administration ("FDA") of the Company's premarket approval application for either the plasma or platelet system (the "PMA Approval"), which occurred in December 2014. The availability of Term Loan B expires on June 15, 2015.  
Third Tranche (Term Loan C)      
Line of Credit Facility [Line Items]      
Loan and security agreement $ 10.0us-gaap_LineOfCredit
/ us-gaap_DebtInstrumentAxis
= cers_ThirdTrancheMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
  $ 10.0us-gaap_LineOfCredit
/ us-gaap_DebtInstrumentAxis
= cers_ThirdTrancheMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
Borrowing conditions   The third tranche of $10.0 million ("Term Loan C") will be available from July 1, 2015 through December 31, 2015, contingent upon the Company achieving trailing six months' revenue at a specified threshold (the "Revenue Event").